Thyrocare TechnologiesNSE:THYROCARE +1.39%87 EBITDA Margin % is 35.71% as of Mar. 2026, which is 0% above its 10-year median of 35.70. GuruFocus rates NSE:THYROCARE with a GF Score™ of 87/100 and a GF Value™ of ₹391.69 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 94.58% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Thyrocare Technologies EBITDA Margin % Related Terms
Thyrocare Technologies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thyrocare Technologies (NSE:THYROCARE) has a EBITDA Margin % of 35.71% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Thyrocare Technologies and its competitors. This is near median its historical median of 35.70. Over the past decade, Thyrocare Technologies' EBITDA Margin % has ranged from 25.07 to 47.23. According to the industry distribution chart, Thyrocare Technologies ranks #11 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 5.4%.
Is Thyrocare Technologies' EBITDA Margin % too high?
Thyrocare Technologies' current EBITDA Margin % of 35.71% is near median its 10-year median of 35.70. Over the past 10 years, this metric has ranged from a low of 25.07 to a high of 47.23. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Thyrocare Technologies' value of 35.71% is 614.2% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #11 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #11 out of 203 companies for EBITDA Margin %. This places Thyrocare Technologies in the top 5% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Thyrocare Technologies' value of 35.71% is 614.2% above this benchmark. Historically, Thyrocare Technologies' own EBITDA Margin % has ranged from 25.07 to 47.23 over the past decade. While the company's 10-year median is 35.70 vs. the industry median of 5.00, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current EBITDA Margin % of 35.71% is 614.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current EBITDA Margin % is 35.71%, which is near median its own 10-year median of 35.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹391.69, compared to a current price of ₹524.40 — trading 33.9% above its estimated fair value. The current EBITDA Margin % is 35.71%, which is near median its 10-year median of 35.70 and 614.2% above the Medical Diagnostics & Research industry median of 5.00. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current EBITDA Margin % is 35.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹524.40 is trading 33.9% above its estimated GF Value™ of ₹391.69.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
EBITDA Margin %: 35.71% (near median its 10-year median of 35.70)
GF Value™: ₹391.69 vs. price of ₹524.40 (33.9% above fair value)
Industry Position: 614.2% above the Medical Diagnostics & Research median (#11 of 203)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score
Get the complete analysis for NSE:THYROCARE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
